期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific,brain-penetrating fusion protein
1
作者 Gillian Bonvicini Stina Syvänen +3 位作者 Ken G.Andersson Merja Haaparanta-Solin Francisco López-Picón Dag Sehlin 《Translational Neurodegeneration》 SCIE 2022年第1期70-83,共14页
Background:Hijacking the transferrin receptor(TfR)is an effective strategy to transport amyloid-beta(Aβ)immuno-positron emission tomography(immunoPET)ligands across the blood-brain barrier(BBB).Such ligands are more ... Background:Hijacking the transferrin receptor(TfR)is an effective strategy to transport amyloid-beta(Aβ)immuno-positron emission tomography(immunoPET)ligands across the blood-brain barrier(BBB).Such ligands are more sensitive and specific than small-molecule ligands at detecting Aβpathology in mouse models of Alzheimer’s disease(AD).This study aimed to determine if this strategy would be as sensitive in rats and to assess how TfR affinity affects BBB transport of bispecific immunoPET radioligands.Methods:Two affinity variants of the rat TfR antibody,OX26,were chemically conjugated to a F(ab′)2 fragment of the anti-Aβantibody,bapineuzumab(Bapi),to generate two bispecific fusion proteins:OX265-F(ab′)2-Bapi and OX2676-F(ab′)2-Bapi.Pharmacokinetic analyses were performed 4 h and 70 h post-injection of radioiodinated fusion proteins in wild-type(WT)rats.[124I]I-OX265-F(ab′)2-Bapi was administered to TgF344-AD and WT rats for in vivo PET imaging.Ex vivo distribution of injected[124I]I-OX265-F(ab′)2-Bapi and Aβpathology were assessed.Results:More[125I]I-OX265-F(ab′)2-Bapi was taken up into the brain 4 h post-administration than[124I]I-OX2676-F(ab′)2-Bapi.[124I]I-OX265-F(ab′)2-Bapi PET visualized Aβpathology with significantly higher signals in the TgF344-AD rats than in the WT littermates without Aβpathology.The PET signals significantly correlated with Aβlevels in AD animals.Conclusion:Affinity to TfR affects how efficiently a TfR-targeting bispecific fusion protein will cross the BBB,such that the higher-affinity bispecific fusion protein crossed the BBB more efficiently.Furthermore,bispecific immunoPET imaging of brain Aβpathology using TfR-mediated transport provides good imaging contrast between TgF344-AD and WT rats,suggesting that this immunoPET strategy has the potential to be translated to higher species. 展开更多
关键词 immunopet Transferrin receptor Alzheimer’s disease AMYLOID-BETA
原文传递
乳腺癌的分子核医学研究进展 被引量:3
2
作者 李翠翠 杨琦 +1 位作者 王荣福 康磊 《中国肿瘤临床》 CAS CSCD 北大核心 2022年第4期193-196,共4页
乳腺癌是一种具有高度异质性、高发病率、高死亡率的癌症。个体化的早期准确诊断和治疗是提高患者生存率的有效手段。分子核医学将分子生物学技术与核医学相结合,在分子、细胞、活体水平对机体生物学行为进行定性和定量研究,是一种高度... 乳腺癌是一种具有高度异质性、高发病率、高死亡率的癌症。个体化的早期准确诊断和治疗是提高患者生存率的有效手段。分子核医学将分子生物学技术与核医学相结合,在分子、细胞、活体水平对机体生物学行为进行定性和定量研究,是一种高度可重复、安全且无创的影像技术,广泛应用于各种恶性肿瘤的诊断、分期、预后预测和疗效评估。本文主要对分子核医学代谢显像、受体显像、基因显像和免疫PET显像在乳腺癌中的应用进行综述。 展开更多
关键词 乳腺癌 分子核医学 代谢显像 受体显像 免疫PET显像
下载PDF
^(89)Zr标记PD-1/PD-L1单抗免疫PET显像应用研究进展
3
作者 郑晨 李翠 《影像研究与医学应用》 2021年第12期3-4,共2页
程序性细胞死亡蛋白-1(PD-1)及其配体(PD-L1)免疫抑制剂是肿瘤免疫治疗领域的研究热点,目前已有10款PD-1/PD-L1单抗药物被批准用于临床肿瘤免疫治疗,但只有部分患者从中获益。^(89)Zr标记的PD-1/PD-L1免疫抑制剂分子探针通过核医学免疫... 程序性细胞死亡蛋白-1(PD-1)及其配体(PD-L1)免疫抑制剂是肿瘤免疫治疗领域的研究热点,目前已有10款PD-1/PD-L1单抗药物被批准用于临床肿瘤免疫治疗,但只有部分患者从中获益。^(89)Zr标记的PD-1/PD-L1免疫抑制剂分子探针通过核医学免疫PET显像可以无创、实时、可重复地检测全身PD-1/PD-L1表达水平,在抗体药物研发、患者筛选、疗效监测和靶向治疗预后评价等方面有重要的应用价值。 展开更多
关键词 ^(89)Zr 免疫PET显像 程序性细胞死亡蛋白-1/程序性细胞死亡配体-1 单抗 免疫抑制剂
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部